Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sugi Holdings (SGIPF) Fair Value & Analysis

Healthcare · US · Market cap $2.9B

Price$16.29
Fair Value$29.89
Upside+83.5%
Quality97/100
Evidence: High Range $22.80 – $60.42

Analysis

Sugi Holdings (SGIPF) currently trades at $16.29, while our model-based Fair Value estimate is $29.89 — implying the stock looks roughly 83.5% undervalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Sugi Holdings Co.,Ltd. operates drugstores in Japan. The company also provides self-care support services, including meal delivery, cancer and other health checkups, specific health guidance, health information, and community comprehensive agreements; health care support, such as medicine support, home-visit dispensing and nursing, prevention programs, shopping assistance, and mobility support services. In addition, it engages in drugstore operation, dispensing pharmacy operation, medical consultation, business in foreign countries, Chinese medicine pharmacy operations, disease prevention and health support, promotion of disabled employment, home visit nursing and elderly home-care support, support for commencement of medical practice, comprehensive staff agency service, and support business for pharmacy operations. Sugi Holdings Co.,Ltd. was founded in 1976 and is headquartered in Obu, Japan.

Open the full interactive analysis →

Similar stocks

JD Health International Inc (JDHIF) +404% Alibaba Health Information Technology Limited (ALBBY) -20% Raia Drogasil S.A (RADL3) -8% Yifeng Pharmacy Chain Co (603939) +5% Clicks Group (CLCGY) +45% Corporativo Fragua, S.A. (CGSBF) +35%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.